

Hedgehog Pathway Inhibitors - Pipeline Insight, 2021

<https://marketpublishers.com/r/HBDDEE6A0C23EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: HBDDEE6A0C23EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Hedgehog Pathway Inhibitors - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hedgehog Pathway Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hedgehog Pathway Inhibitors Understanding

Hedgehog Pathway Inhibitors: Overview

The hedgehog (Hh) signaling pathway is highly conserved in organisms ranging from insects to mammals, and plays an important role in embryogenesis and tissue homeostasis. In mammalian cells, Hh family proteins bind to the 12-transmembrane glycoprotein patched (Ptch) protein to activate the 7-transmembrane protein smoothed (Smo). Then, Smo activates transcription factors in the Gli family via formation of a cytosolic complex. Activated Gli proteins then translocate into the nucleus to induce transcription of target genes.

Aberrant activation of the Hh pathway is associated with the initiation and progression of various cancers. Blocking the Hh pathway has been reported to inhibit cancer cell

growth and tumor development so the Hh signaling pathway has critical therapeutic potential with the JAK-STAT signaling pathway. These inhibitors have therapeutic application in the

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hedgehog Pathway Inhibitors R&D. The therapies under development are focused on novel approaches for Hedgehog Pathway Inhibitors.

Hedgehog Pathway Inhibitors Emerging Drugs Chapters

This segment of the Hedgehog Pathway Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hedgehog Pathway Inhibitors Emerging Drugs

Glasdegib - Pfizer

Glasdegib is a oral Hedgehog pathway inhibitor. It is approved for Acute myeloid leukaemia but for indications such as Chronic myelomonocytic leukaemia, Myelofibrosis, Glioblastoma, Graft-versus-host disease, Haematological malignancies, Solid tumours it is in different phases of development.

Further product details are provided in the report.....

Hedgehog Pathway Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Hedgehog Pathway Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Hedgehog Pathway Inhibitors

There are approx. 10+ key companies which are developing the Hedgehog Pathway Inhibitors. The companies which have their Hedgehog Pathway Inhibitors drug

candidates in the most advanced stage, i.e. phase II include, Pfizer.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hedgehog Pathway Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hedgehog Pathway Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hedgehog Pathway Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hedgehog Pathway Inhibitors drugs.

Hedgehog Pathway Inhibitors Report Insights

Hedgehog Pathway Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Hedgehog Pathway Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Hedgehog Pathway Inhibitors drugs?

How many Hedgehog Pathway Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Hedgehog Pathway Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hedgehog Pathway Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hedgehog Pathway Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Pfizer

Pulmatrix

Eli Lilly and Company

Suzhou Kintor Pharmaceuticals

IMPACT Therapeutics

Key Products

Glasdegib

Itraconazole inhaled

Taladegib

GT 1708F

IMP 5471

Research programme: hedgehog pathway inhibitors

Contents

Introduction

Executive Summary

Hedgehog Pathway Inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Hedgehog Pathway Inhibitors - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Hedgehog Pathway Inhibitors companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Hedgehog Pathway Inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Glasdegib - Pfizer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

GT 1708F: Suzhou Kintor Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Hedgehog Pathway Inhibitors Key Companies

Hedgehog Pathway Inhibitors Key Products

Hedgehog Pathway Inhibitors- Unmet Needs

Hedgehog Pathway Inhibitors- Market Drivers and Barriers

Hedgehog Pathway Inhibitors- Future Perspectives and Conclusion

Hedgehog Pathway Inhibitors Analyst Views

Hedgehog Pathway Inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Hedgehog Pathway Inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Hedgehog Pathway Inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Hedgehog Pathway Inhibitors - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/HBDDEE6A0C23EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HBDDEE6A0C23EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970